Previous infection with COVID-19 protects most people against reinfection for over six months, but those over the age of 65 are more likely to get infected again, found a peer reviewed study published in The Lancet.  In the world’s first large-scale study of COVID-19 reinfections, researchers from Denmark, Sweden and the United Kingdom discovered that […] Continue reading ->
The contribution COVID-19 vaccines can make to beating the pandemic will depend on the extent to which they are produced at scale, priced affordably, and deployed globally, says the first peer reviewed study on equitable access to vaccines, published in The Lancet on Friday.  The Lancet article comes in the wake of a joint appeal […] Continue reading ->
News of the successful trial results of the Russian Sputnik vaccine, published on Wednesday by The Lancet has shored up the prospects of quick vaccine access for dozens of countries that have pinned their hopes on Russian or Chinese vaccine alternatives – as rich countries buy up the bulk of supplies of high-tech vaccines and […] Continue reading ->
Fulfilling the legacy of its pioneering name, the Russian Sputnik V vaccine, was over 91% effective in preventing symptomatic COVID-19 cases and 100% effective in preventing severe COVID, according to results published Tuesday in The Lancet.  Globally, that means that the Sputnik vaccine joins the club with just two other coronavirus vaccines that have demonstrated […] Continue reading ->
Two new studies published this week highlight the challenges to health policy posed by COVID-19 – with seriously ill COVID-19 patients continuing to suffer with “Long COVID”  months after being released from the hospital – while completely asymptomatic cases drive more than half of overall disease transmission.   More than three quarters of patients diagnosed with […] Continue reading ->
Just hours after the UK jabbed its first citizen against the coronavirus, researchers have confirmed that Oxford’s vaccine is safe and effective in the first peer-reviewed publication of a Phase III coronavirus vaccine trial yet.  “The results for me are very compelling,” said AstraZeneca’s executive vice president Mene Pangalos on Wednesday at a press conference. […] Continue reading ->
The COVID-19 pandemic, along with the continued global rise in chronic illness and related disease risk factors, such as obesity, high blood sugar, and outdoor air pollution exposures, seen over the past 30 years has created a ‘perfect storm’, fueling COVID-19 deaths, says a new study published Thursday in The Lancet . The global disease […] Continue reading ->
About 1.7 billion people, or 22% of the world’s population, has at least one underlying health condition that puts them at increased risk of becoming seriously ill with COVID-19, according to a new modelling study published in Lancet Global Health.   Based on the new assessment, about 4% of the world’s population, in total, is at […] Continue reading ->
A COVID-19 vaccine candidate made by Chinese researchers successfully induced the development of neutralizing and binding antibodies against SARS-CoV-2, the virus that causes COVID-19, according to early results from a non-randomized phase I clinical trial published Friday in The Lancet.  The trial results follow on to results announced by Moderna earlier this week, which found […] Continue reading ->